| Updated in 10/11/2018 10:25:02 AM |
Viewed: 507 times |
(Journal Article) |
EMBO molecular medicine 5 (9): 1351-66 (2013)
Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia.
Jung Eun Park
,
Hiu Fung Yuen
,
Jian Biao Zhou
,
Abdul Qader O Al-Aidaroos
,
Ke Guo
,
Peter J Valk
,
Shu Dong Zhang
,
Wee Joo Chng
,
Cheng William Hong
,
Ken Mills
,
Qi Zeng
ABSTRACT
FLT3-ITD mutations are prevalent mutations in acute myeloid leukaemia (AML). PRL-3, a metastasis-associated phosphatase, is a downstream target of FLT3-ITD. This study investigates the regulation and function of PRL-3 in leukaemia cell lines and AML patients associated with FLT3-ITD mutations. PRL-3 expression is upregulated by the FLT3-STAT5 signalling pathway in leukaemia cells, leading an activation of AP-1 transcription factors via ERK and JNK pathways. PRL-3-depleted AML cells showed a significant decrease in cell growth. Clinically, high PRL-3 mRNA expression was associated with FLT3-ITD mutations in four independent AML datasets with 1158 patients. Multivariable Cox-regression analysis on our Cohort 1 with 221 patients identified PRL-3 as a novel prognostic marker independent of other clinical parameters. Kaplan-Meier analysis showed high PRL-3 mRNA expression was significantly associated with poorer survival among 491 patients with normal karyotype. Targeting PRL-3 reversed the oncogenic effects in FLT3-ITD AML models in vitro and in vivo. Herein, we suggest that PRL-3 could serve as a prognostic marker to predict poorer survival and as a promising novel therapeutic target for AML patients.